Despite all the buzz around Sarepta and concerns about Elevidys, industry watchers aren’t convinced this current controversy ...

Elevidys, approved by the FDA in 2024 for Duchenne, generated nearly $375M in net product revenue for Sarepta (NASDAQ: SRPT) in Q1 2025.

By Bhanvi Satija (Reuters) -The U.S. Food and Drug Administration is planning to ask Sarepta Therapeutics to voluntarily stop all shipments of its gene therapy Elevidys, a source familiar with the ...

Sarepta downgraded as company suspends guidance after latest Elevidys death Jun. 16, 2025 11:31 AM ET Sarepta Therapeutics, Inc. (SRPT) Stock RHHBY, RHHBF By: Dulan Lokuwithana, SA News Editor 8 ...

Although Sarepta initially appeared to have avoided the worst possible outcome for Elevidys—a market withdrawal—thanks to the gene therapy’s new black box warning, the FDA is signaling ...

Nevertheless, on the same day, Sarepta assured investors that “the benefit-risk of ELEVIDYS remains positive.” Next, on June 15, 2025, Sarepta announced that a second patient treated with ...

Pharma FDA investigates patient deaths after treatment with Sarepta's Duchenne gene therapy Elevidys By Angus Liu Jun 25, 2025 10:26am Sarepta Therapeutics gene therapy U.S. FDA FDA investigation ...

Sarepta said it is convening with an independent panel of experts in Duchenne and liver health to evaluate a proposed immunosuppression regimen. More than 900 individuals have received Elevidys ...

(Reuters) -The U.S. Food and Drug Administration is planning to request Sarepta Therapeutics to voluntarily stop all shipments of its gene therapy, Elevidys, a source familiar with the matter told ...

On March 18, 2025, Sarepta announced that a patient that had been treated with Elevidys died after suffering acute liver failure. On this news, the price of Sarepta stock fell $27.81 per share, or ...